Expertise in
25
conditions

Dr. Muhammad A. Irfan

Imran Nathani, MD PA
Tomball, TX
Expertise in
25
conditions
Specialties:Internal Medicine
Accepting New Patients
Offers Telehealth
Expertise in
25
conditions
OverviewInsuranceLocationsClinical Research

Overview

Muhammad Irfan is an Internal Medicine provider in Tomball, Texas. Dr. Irfan is highly rated in 25 conditions, according to our data. His top areas of expertise are Necrosis, Lung Metastases, Acute Kidney Failure, Gastrostomy, and Colonoscopy. Dr. Irfan is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in TX
Hospital Affiliations
St Luke's Hospital At The Vintage
Hca Houston Healthcare Tomball
Houston Methodist Willowbrook Hospital
Languages Spoken
English
Spanish
Urdu
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Community Health
  •  Friday Health
  •  Oscar
  •  UnitedHealthcare
  •  Humana

Locations

IMRAN NATHANI, MD PA
27721 Tomball Pkwy, Suite 200, Tomball, TX 77375
281-351-6800

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

13 Total Publications

Structure switching aptamer enhance sensitivity and specificity of photonic crystal-based sensors for RSV-G protein detection.
Structure switching aptamer enhance sensitivity and specificity of photonic crystal-based sensors for RSV-G protein detection.
Journal: Biosensors & bioelectronics
Published: September 04, 2024
Similar Doctors
Expertise in
23
conditions
Dr. Paolo Strati
Internal Medicine
Expertise in
23
conditions
Dr. Paolo Strati
Internal Medicine

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (29.2 mi)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paolo Strati is an Internal Medicine provider in Houston, Texas. Dr. Strati is highly rated in 23 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Expertise in
34
conditions
Dr. Mohammad F. Bilal
Internal Medicine
Expertise in
34
conditions
Dr. Mohammad F. Bilal
Internal Medicine
1 Baylor Plz, 
Houston, TX 
 (29.0 mi)
713-798-5928
Languages Spoken:
English
Accepting New Patients

Mohammad Bilal is an Internal Medicine provider in Houston, Texas. Dr. Bilal is highly rated in 34 conditions, according to our data. His top areas of expertise are Gastrointestinal Bleeding, Gallbladder Disease, Cholecystitis, Endoscopy, and Colonoscopy. Dr. Bilal is currently accepting new patients.

Expertise in
24
conditions
Dr. Salim S. Virani
Internal Medicine
Expertise in
24
conditions
Dr. Salim S. Virani
Internal Medicine
6565 Fannin St Ste B157, 
Houston, TX 
 (29.0 mi)
713-798-5800
Languages Spoken:
English

Salim Virani is an Internal Medicine provider in Houston, Texas. Dr. Virani is highly rated in 24 conditions, according to our data. His top areas of expertise are Atherosclerosis, Coronary Heart Disease, High Cholesterol, Coronary Artery Bypass Graft (CABG), and Percutaneous Coronary Intervention (PCI).

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile